The clinically important question, however, is whether azithromycin itself causes
cardiovascu lar death or is simply a marker of increased risk. Patients who are sick enough …

The FDA recently approved labeling changes advising against the use of azithromycin in
patients with known cardiovascular risk factors such as QT-interval prolongation …

A comment on this article appears in" Cardiovascular risks with azithromycin." N Engl J Med.
2013 Aug 8; 369 (6): 580-1. A comment on this article appears in" Cardiovascular risks with …

Background Azithromycin has been used for many years for the treatment of patients with
various types of bacterial infections, as well as for the secondary prevention of coronary …

Background Although several macrolide antibiotics are proarrhythmic and associated with
an increased risk of sudden cardiac death, azithromycin is thought to have minimal …

The FDA has updated azithromycin package labeling to include the risk of prolonged
cardiac repolarization and QT prolongation, which increase the possibility of cardiac …

Importance Azithromycin is one of the most commonly prescribed antibiotics in the US. It has
been associated with an increased risk of cardiovascular death in some observational …

Azithromycin is a broad-spectrum macrolide antibiotic, marketed in the United States under
the trade name Zithromax or Zmax/Z-pak, used to treat or prevent a range of common …

Recent evidence, though conflicting, suggests an association between azithromycin use and
cardiovascular death. We conducted a systematic review and meta-analysis to evaluate the …

Background Azithromycin use is associated with an increased risk of death from
cardiovascular causes among patients at high baseline risk. Whether azithromycin confers a …